Spots Global Cancer Trial Database for intrahepatic cholangiocarcinoma
Every month we try and update this database with for intrahepatic cholangiocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | NCT05251662 | Intrahepatic Ch... | Sintilimab IBI305 GEMOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | NCT05239169 | Biliary Tract C... Intrahepatic Ch... Hilar Cholangio... Distal Cholangi... Gall Bladder Ca... | Durvalumab Tremelimumab Capecitabine | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | NCT05535647 | Intrahepatic Ch... | Regorafenib and... FOLFOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | NCT02415036 | Hepatocellular ... Intrahepatic Ch... | Delcath Hepatic... Melphalan | 18 Years - | Delcath Systems Inc. | |
| Surgery for Recurrent Intrahepatic Cholangiocarcinoma | NCT04072250 | Cholangiocarcin... Recurrence Chol... Re-hepatectomy | hepatectomy | 18 Years - 75 Years | Chang Gung Memorial Hospital | |
| Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma | NCT02526771 | Intrahepatic Ch... | conventional ly... unconventional ... | 18 Years - 70 Years | Eastern Hepatobiliary Surgery Hospital | |
| Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma | NCT04077983 | Cholangiocarcin... | combined therap... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma | NCT06290739 | Intrahepatic Ch... Machine Learnin... | lymph nodes dis... | 18 Years - 80 Years | West China Hospital | |
| Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk | NCT05672537 | Durvalumab Intrahepatic Ch... Gemcis | Durvalumab Surgery Gemcitabine Cisplatin | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | NCT06417606 | Intrahepatic Ch... | Lenvatinib | 18 Years - 80 Years | Tongji Hospital | |
| Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma | NCT04961788 | Intrahepatic Ch... | Gemox combimed ... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma | NCT04276090 | Bile Duct Neopl... Colorectal Neop... | Hepatic artery ... Hepatic artery ... Systemic chemot... Systemic chemot... | 18 Years - | University of Kentucky | |
| Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT06208462 | Intrahepatic Ch... | Adebrelimab Lenvatinib Gemcitabine Oxaliplatin | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer | NCT02238613 | Intrahepatic Ch... Cholangiocarcin... Ampullary Carci... Biliary Obstruc... | radioactive ste... plastic stent | 18 Years - 80 Years | 307 Hospital of PLA | |
| A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | NCT03251443 | Intrahepatic Ch... Second-line Tre... | Apatinib | 18 Years - | Peking Union Medical College Hospital | |
| A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma | NCT06290739 | Intrahepatic Ch... Machine Learnin... | lymph nodes dis... | 18 Years - 80 Years | West China Hospital | |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
| Treat Primary and Metastatic Liver Tumors | NCT05240040 | Intrahepatic Ch... Liver Tumor Metastatic Canc... Metastatic Live... | 18 Years - | Methodist Health System | ||
| The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer | NCT05422690 | Intrahepatic Ch... | Induction Chemo... Concurrent Y-90... Consolidation D... | 18 Years - | Inova Health Care Services | |
| A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | NCT04479904 | Intrahepatic Ch... | Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma | NCT01938729 | Intrahepatic Ch... Peripheral Chol... Cholangiolar Ca... Cholangiocellul... | Liver resection... FLOXURIDINE DEXAMETHASONE GEMCITABINE | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | NCT05239169 | Biliary Tract C... Intrahepatic Ch... Hilar Cholangio... Distal Cholangi... Gall Bladder Ca... | Durvalumab Tremelimumab Capecitabine | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma | NCT02807181 | Intrahepatic Ch... | Cisplatin-gemci... Radiation: SIRT... | 18 Years - | Sirtex Medical | |
| Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) | NCT01862315 | Intrahepatic Ch... Peripheral Chol... Cholangiolar Ca... Cholangiocellul... | Floxuridine (FU... dexamethasone Gemcitabine Oxaliplatin MRI Research blood ... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma | NCT02807181 | Intrahepatic Ch... | Cisplatin-gemci... Radiation: SIRT... | 18 Years - | Sirtex Medical | |
| VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway | NCT01917370 | Intrahepatic Ch... | surgical treatm... | 16 Years - 90 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study | NCT05930119 | Intrahepatic Ch... | HMPL-453 Rabeprazole | 18 Years - 55 Years | Hutchmed | |
| Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | NCT05251662 | Intrahepatic Ch... | Sintilimab IBI305 GEMOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations | NCT04087876 | Intrahepatic Ch... | derazantinib | 18 Years - | Basilea Pharmaceutica | |
| Liver Transplantation for Early Intrahepatic Cholangiocarcinoma | NCT02878473 | Intrahepatic Ch... | Deceased donor ... | 18 Years - 65 Years | University Health Network, Toronto | |
| Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04669496 | Intrahepatic Ch... PD1 Antibody Lenvatinib Gemox Chemother... | Neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery | NCT04891289 | Intrahepatic Ch... | Gemcitabine Oxaliplatin Dexamethasone Floxuridine (FU... Implanted Medic... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | NCT04561453 | Biliary Tract C... Cholangiocarcin... Gallbladder Can... Intrahepatic Ch... Perihilar Chola... Extrahepatic Ch... Hilar Cholangio... Distal Bile Duc... | Multi-Platform ... | 18 Years - | University of Washington | |
| TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | NCT05247996 | Intrahepatic Ch... | Transcatheter a... Multi-target Dr... Immunocheckpoin... Systemic Intrav... | 18 Years - | The Central Hospital of Lishui City | |
| Hepatic Artery Infusion (HAI) Program at Duke University | NCT04511793 | Metastatic Colo... Liver Cancer Intrahepatic Ch... | Medtronic Synch... | 18 Years - 80 Years | Duke University | |
| Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma | NCT04301778 | Unresectable In... | Durvalumab SNDX-6352 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| HAIC Versus Systemic Chemotherapy for Unresectable ICC | NCT03771846 | Intrahepatic Ch... | irinotecan, oxa... gemcitabine and... | 18 Years - 75 Years | Sun Yat-sen University | |
| TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | NCT05247996 | Intrahepatic Ch... | Transcatheter a... Multi-target Dr... Immunocheckpoin... Systemic Intrav... | 18 Years - | The Central Hospital of Lishui City | |
| Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | NCT03951597 | Cholangiocarcin... | combined therap... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | NCT06134193 | Carcinoma Intrahepatic Ch... Gallbladder Can... Surufatinib Angiogenesis In... Tislelizumab Antineoplastic ... Immunotherapy | HAIC Surufatinib Tislelizumab | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT06208462 | Intrahepatic Ch... | Adebrelimab Lenvatinib Gemcitabine Oxaliplatin | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma | NCT02548195 | Cholangiocarcin... | oxaliplatin and... capecitabine | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Stereotactic Body Radiotherapy for Liver Tumors | NCT01347333 | Liver Metastase... Hepatocellular ... Intrahepatic Ch... | Stereotactic bo... Stereotactic Bo... | 18 Years - | Mercy Research | |
| HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma | NCT05489692 | Intrahepatic Ch... | hepatic arteria... | 18 Years - | Sun Yat-sen University | |
| Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | NCT05009953 | Advanced Biliar... Intrahepatic Ch... Extrahepatic Ch... Gallbladder Car... | Irinotecan Lipo... SG001 Fluorouracil Leucovorin | 18 Years - | CSPC Ouyi Pharmaceutical Co., Ltd. | |
| HAIC Combined With Donafenib and Sintilimab for Unresectable ICC | NCT05348811 | Cholangiocarcin... | HAIC combined w... | 18 Years - 75 Years | Zhongda Hospital | |
| Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers | NCT04211168 | Advanced Biliar... | Toripalimab plu... | 18 Years - | Peking Union Medical College Hospital | |
| A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | NCT06375642 | Intrahepatic Ch... | Adebrelimab | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway | NCT01917370 | Intrahepatic Ch... | surgical treatm... | 16 Years - 90 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | NCT04527679 | Cholangiocarcin... | GC combined Len... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma | NCT06313554 | Intrahepatic Ch... | Surufatinib、Tor... | 18 Years - 75 Years | Fudan University | |
| HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT) | NCT06313203 | Intrahepatic Ch... Chemotherapy Ef... | Floxuridine Selective Inter... | 18 Years - | Oslo University Hospital | |
| Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma | NCT04413734 | Intrahepatic Ch... | Combination the... Mono-chemothera... | 18 Years - 80 Years | Zhejiang University | |
| The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases | NCT05896956 | Biliary Tract D... Gallbladder Can... Extrahepatic Bi... Intrahepatic Ch... Biliary Tract N... Gall Stone | no intervention... | 18 Years - 74 Years | RenJi Hospital | |
| Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy | NCT06375915 | Intrahepatic Ch... | radioembolizati... Durvalumab Cisplatin Gemcitabine | 18 Years - 80 Years | IRCCS San Raffaele | |
| Bortezomib in Intrahepatic Cholangiocellular Carcinoma | NCT03345303 | Intrahepatic Ch... | Bortezomib | 18 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
| A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | NCT04479904 | Intrahepatic Ch... | Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC | NCT05019677 | Intrahepatic Ch... | GP+PD-1+Tight | 18 Years - 75 Years | Fudan University | |
| Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer | NCT05010681 | Intrahepatic Ch... | Sintilimab Lenvatinib | 18 Years - | Fudan University | |
| Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma | NCT06192797 | Cholangiocarcin... | HAIC Lenvatinib plus... | 18 Years - 75 Years | Tongji Hospital | |
| PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | NCT05565794 | Intrahepatic Ch... FGFR2 Gene Muta... FGFR2 Gene Rear... FGFR2 Gene Tran... | Pemigatinib | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | NCT05913661 | Carcinoma Intrahepatic Ch... Digestive Syste... PD-1 Inhibitor First-line Trea... | Pemigatinib PD-1 Inhibitors | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases | NCT05285358 | Distal Bile Duc... Gallbladder Car... Intrahepatic Ch... Metastatic Mali... Stage IV Distal... Stage IV Intrah... Stage IV Intrah... Stage IVB Gallb... | Cisplatin Gemcitabine Nab-paclitaxel Quality-of-Life... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma | NCT03320980 | Hilar Cholangio... Intrahepatic Ch... | RALPPS portal vein emb... | 18 Years - 80 Years | Moscow Clinical Scientific Center | |
| Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma | NCT01862276 | Intrahepatic Ch... | - | Kansai Hepatobiliary Oncology Group | ||
| Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment | NCT05328167 | Intrahepatic Ch... | Perflutren Prot... Contrast-Enhanc... | 18 Years - | Thomas Jefferson University | |
| Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) | NCT01862315 | Intrahepatic Ch... Peripheral Chol... Cholangiolar Ca... Cholangiocellul... | Floxuridine (FU... dexamethasone Gemcitabine Oxaliplatin MRI Research blood ... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT) | NCT06313203 | Intrahepatic Ch... Chemotherapy Ef... | Floxuridine Selective Inter... | 18 Years - | Oslo University Hospital | |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | NCT05712356 | Cholangiocarcin... Gallbladder Can... Gallbladder Car... Intrahepatic Ch... Extrahepatic Ch... Bile Duct Cance... Gall Bladder Ca... Gall Bladder Ca... | LSTA1 Durvalumab Cisplatin Gemcitabine FOLFOX regimen Placebo | 18 Years - | Lisata Therapeutics, Inc. | |
| Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery | NCT04891289 | Intrahepatic Ch... | Gemcitabine Oxaliplatin Dexamethasone Floxuridine (FU... Implanted Medic... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery | NCT06050252 | Intrahepatic Ch... | Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Durvalumab Gemcitabine Magnetic Resona... Resection | 18 Years - | National Cancer Institute (NCI) | |
| Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | NCT06417606 | Intrahepatic Ch... | Lenvatinib | 18 Years - 80 Years | Tongji Hospital | |
| Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study | NCT05342194 | Intrahepatic Ch... | Toripalimab Lenvatinib mesy... Placebo IV Oral placebo Oxaliplatin for... Gemcitabine hyd... Cisplatin | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | NCT02834013 | Acinar Cell Car... Adenoid Cystic ... Adrenal Cortica... Adrenal Gland P... Anal Canal Neur... Anal Canal Undi... Angiosarcoma Apocrine Neopla... Appendix Mucino... Bartholin Gland... Basal Cell Carc... Bladder Adenoca... Breast Metaplas... Cervical Adenoc... Cholangiocarcin... Chordoma Colorectal Squa... Desmoid Fibroma... Endometrial Tra... Endometrioid Ad... Esophageal Neur... Esophageal Undi... Extrahepatic Bi... Extramammary Pa... Fallopian Tube ... Fallopian Tube ... Fibromyxoid Tum... Gallbladder Car... Gastric Neuroen... Gastric Squamou... Gastric Undiffe... Gastrointestina... Gestational Tro... Giant Cell Carc... Human Papilloma... Intestinal Neur... Intrahepatic Ch... Lung Neuroendoc... Lung Sarcomatoi... Major Salivary ... Malignant Odont... Malignant Perip... Malignant Solid... Malignant Testi... Metastatic Mali... Metastatic Pitu... Minimally Invas... Mixed Mesoderma... Mucinous Adenoc... Mucinous Cystad... Nasal Cavity Ad... Nasal Cavity Ca... Nasopharyngeal ... Nasopharyngeal ... Nasopharyngeal ... Oral Cavity Car... Oropharyngeal U... Ovarian Adenoca... Ovarian Germ Ce... Ovarian Mucinou... Ovarian Squamou... Ovarian Transit... Pancreatic Acin... Pancreatic Neur... Paraganglioma Paranasal Sinus... Paranasal Sinus... Parathyroid Gla... PEComa Penile Squamous... Peritoneal Meso... Placental Chori... Primary Periton... Pseudomyxoma Pe... Rare Disorder Scrotal Squamou... Seminal Vesicle... Seminoma Serous Cystaden... Small Intestina... Small Intestina... Spindle Cell Ne... Teratoma With S... Testicular Non-... Thyroid Gland C... Tracheal Carcin... Transitional Ce... Ureter Adenocar... Ureter Squamous... Urethral Adenoc... Urethral Squamo... Vaginal Adenoca... Vaginal Squamou... Vulvar Carcinom... | Biospecimen Col... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib in Intrahepatic Cholangiocellular Carcinoma | NCT03345303 | Intrahepatic Ch... | Bortezomib | 18 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
| GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence | NCT05557578 | Intrahepatic Ch... | Tislelizumab co... | 18 Years - 75 Years | Zhejiang Cancer Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
